Next Article in Journal
Electrospun Polyethylene Terephthalate Nanofibers Loaded with Silver Nanoparticles: Novel Approach in Anti-Infective Therapy
Previous Article in Journal
Changes in Spinal and Corticospinal Excitability in Patients with Chronic Ankle Instability: A Systematic Review with Meta-Analysis
Open AccessArticle

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology

City of Hope, Dept. of Medical Oncology and Therapeutics Research, Duarte, CA 91010, USA
Abbott Molecular, Des Plaines, IL 60018, USA
Center for BioSystems Science and Engineering, Indian Institute of Science, Bangalore 560012, India
City of Hope, Center for Informatics, Duarte, CA 91010, USA
City of Hope, Dept. of Computational & Quantitative Medicine, Duarte, CA 91010, USA
University of Nebraska Medical Center, Dept. of Biochemistry and Molecular Biology, Omaha, NE 68198, USA
City of Hope, Dept. of Diagnostic Radiology, Duarte, CA 91010, USA
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(7), 1038;
Received: 20 May 2019 / Revised: 3 July 2019 / Accepted: 11 July 2019 / Published: 16 July 2019
(This article belongs to the Section Pulmonology)
PDF [3031 KB, uploaded 16 July 2019]


Small cell lung cancer (SCLC) is an aggressive neuroendocrine disease with an overall 5 year survival rate of ~7%. Although patients tend to respond initially to therapy, therapy-resistant disease inevitably emerges. Unfortunately, there are no validated biomarkers for early-stage SCLC to aid in early detection. Here, we used readouts of lesion image characteristics and cancer morphology that were based on fractal geometry, namely fractal dimension (FD) and lacunarity (LC), as novel biomarkers for SCLC. Scanned tumors of patients before treatment had a high FD and a low LC compared to post treatment, and this effect was reversed after treatment, suggesting that these measurements reflect the initial conditions of the tumor, its growth rate, and the condition of the lung. Fractal analysis of mitochondrial morphology showed that cisplatin-treated cells showed a discernibly decreased LC and an increased FD, as compared with control. However, treatment with mdivi-1, the small molecule that attenuates mitochondrial division, was associated with an increase in FD as compared with control. These data correlated well with the altered metabolic functions of the mitochondria in the diseased state, suggesting that morphological changes in the mitochondria predicate the tumor’s future ability for mitogenesis and motogenesis, which was also observed on the CT scan images. Taken together, FD and LC present ideal tools to differentiate normal tissue from malignant SCLC tissue as a potential diagnostic biomarker for SCLC. View Full-Text
Keywords: small cell lung cancer; radiology; fractal dimension; lacunarity; mitochondria small cell lung cancer; radiology; fractal dimension; lacunarity; mitochondria

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Mambetsariev, I.; Mirzapoiazova, T.; Lennon, F.; Jolly, M.K.; Li, H.; Nasser, M.W.; Vora, L.; Kulkarni, P.; Batra, S.K.; Salgia, R. Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. J. Clin. Med. 2019, 8, 1038.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top